WO2016177318A1 - 一种酰胺类化合物及其制备方法和用途 - Google Patents

一种酰胺类化合物及其制备方法和用途 Download PDF

Info

Publication number
WO2016177318A1
WO2016177318A1 PCT/CN2016/080952 CN2016080952W WO2016177318A1 WO 2016177318 A1 WO2016177318 A1 WO 2016177318A1 CN 2016080952 W CN2016080952 W CN 2016080952W WO 2016177318 A1 WO2016177318 A1 WO 2016177318A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
aryl
alkoxy
cycloalkyl
Prior art date
Application number
PCT/CN2016/080952
Other languages
English (en)
French (fr)
Inventor
吕亮
王刚
单中刚
刘吉永
孙芹
王军锋
李斌
Original Assignee
沈阳中化农药化工研发有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201510226412.1A external-priority patent/CN106187893B/zh
Priority claimed from CN201510226786.3A external-priority patent/CN106187939B/zh
Application filed by 沈阳中化农药化工研发有限公司 filed Critical 沈阳中化农药化工研发有限公司
Priority to US15/551,401 priority Critical patent/US10315998B2/en
Priority to EP16789312.2A priority patent/EP3293179A4/en
Priority to CN201680004319.9A priority patent/CN107108515B/zh
Priority to BR112017014498-0A priority patent/BR112017014498B1/pt
Publication of WO2016177318A1 publication Critical patent/WO2016177318A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/56—1,2-Diazoles; Hydrogenated 1,2-diazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
    • A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Definitions

  • the invention belongs to the field of fungicides. It relates to an amide compound, a preparation method thereof and use thereof.
  • JP62249975 discloses pyrazole amides KC 1 , KC 2 , KC 3 and KC 4 (compounds 3 , 2 , 10 and 4 , respectively) and their bactericidal activity.
  • JP 5657776 discloses a thiazole amide compound KC 5 (Compound 1 in the patent) and its bactericidal activity.
  • Pesticide Science (1993), 38(1), 1-7 discloses the thiazole amide compound KC 6 (compound XIV in the article) and its bactericidal activity.
  • the object of the present invention is to provide an amide compound having better bactericidal activity, which can be applied to the prevention and treatment of diseases in agriculture and forestry.
  • the present invention provides amide compounds as shown in Formula I:
  • R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each independently selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 12 alkyl, C 1 -C 12 alkoxy, C 1 -C 12 haloalkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, hydroxy-C 1 to C 6 alkyl group, C 1 -C 6 alkoxy group - C 1 -C 6 alkyl group, C 3 -C 6 cycloalkyl group -C 1 -C 6 alkyloxy group -C 1 -C 6 alkyl group, C 1 -C 6 haloalkoxy-C 1 -C 6 alkyl group, C 3 -C 8 alkenyloxy-C 1 -C 6 alkyl group, C 3 -C 8 al
  • aryl group is selected from the group consisting of a benzene ring, a 5- or 6-membered heterocyclic ring having 1 to 3 hetero atoms, or a 5- or 6-membered heterocyclic ring having benzene and having 1 to 3 hetero atoms;
  • R 7 is selected from halogen, nitro, cyano, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl;
  • Q is selected from Q 1 or Q 2
  • R 8 is selected from a C 1 -C 3 alkyl group, a C 1 -C 3 haloalkyl group or a C 3 -C 6 cycloalkyl group;
  • R 9 is selected from the group consisting of hydrogen, halogen or methyl
  • R 8 is selected from the group consisting of difluoromethyl, R 9 is not hydrogen;
  • R 10 and R 11 are each independently selected from a C 1 -C 6 alkyl group, a C 1 -C 6 haloalkyl group or a C 3 -C 6 cycloalkyl group.
  • R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each independently selected from the group consisting of hydrogen, halogen, cyano, C 1 -C 12 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, C 3 -C 6 halocycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, hydroxy-C 1 to C 3 alkyl group, C 1 - C 3 alkoxy group - C 1 - C 3 alkyl group, C 3 - C 6 cycloalkyl group - C 1 - C 3 alkyloxy group - C 1 -C 3 alkyl group, C 1 -C 3 haloalkoxy-C 1 -C 3 alkyl group, C 3 -C 6 alkenyloxy-C 1 -C 3 alkyl group, C 3 -C 6 al
  • aryl group is selected from the group consisting of a benzene ring, a 5- or 6-membered heterocyclic ring having 1 to 3 hetero atoms, or a 5- or 6-membered heterocyclic ring having benzene and having 1 to 3 hetero atoms;
  • R 7 is selected from halogen, nitro, cyano, C 1 -C 3 alkyl or C 1 -C 3 haloalkyl;
  • Q is selected from Q 1 or Q 2
  • R 8 is selected from a C 1 -C 3 alkyl group, a C 1 -C 3 haloalkyl group or a C 3 -C 6 cycloalkyl group;
  • R 9 is selected from the group consisting of hydrogen, halogen or methyl
  • R 8 is selected from the group consisting of difluoromethyl, R 9 is not hydrogen;
  • R 10 and R 11 are each independently selected from a C 1 -C 3 alkyl group, a C 1 -C 3 haloalkyl group or a C 3 -C 6 cycloalkyl group.
  • R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, cyano, C 1 -C 12 alkyl, C 1 -C 3 Alkoxy group, C 1 -C 6 haloalkyl group, C 3 -C 6 cycloalkyl group, C 3 -C 6 halocycloalkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 Alkynyl group, hydroxy-C 1 -C 3 alkyl group, C 1 -C 3 alkoxy group -C 1 -C 3 alkyl group, C 3 -C 6 cycloalkyl-C 1 -C 3 alkane Alkoxy-C 1 -C 3 alkyl group, C 1 -C 3 haloalkoxy-C 1 -C 3 alkyl group, C 3 -C 6 alkenyloxy-C 1
  • aryl group is selected from the group consisting of benzene ring, furan, thiophene, pyrrole, pyrazole, oxazole, isoxazole, thiazolyl, pyridine, pyrazine, pyrimidine, pyridazine, benzoxazole, benzothiazole, quinoxaline Or quinazolinyl;
  • R 7 is selected from the group consisting of fluorine, chlorine, bromine, iodine, nitro, cyano, C 1 -C 3 alkyl or C 1 -C 3 haloalkyl;
  • Q is selected from Q 1 or Q 2
  • R 8 is selected from a C 1 -C 3 alkyl group, a C 1 -C 3 haloalkyl group or a C 3 -C 6 cycloalkyl group;
  • R 9 is selected from the group consisting of hydrogen, halogen or methyl
  • R 8 is selected from the group consisting of difluoromethyl, R 9 is not hydrogen;
  • R 10 and R 11 are each independently selected from a C 1 -C 3 alkyl group, a C 1 -C 3 haloalkyl group or a C 3 -C 6 cycloalkyl group.
  • R 1 is selected from the group consisting of fluorine, a C 1 -C 3 alkyl group or a C 1 -C 3 haloalkyl group;
  • R 2 , R 3 , R 4 and R 5 are each independently selected from the group consisting of hydrogen, fluorine, a C 1 -C 3 alkyl group or a C 1 -C 3 haloalkyl group;
  • R 6 is selected from the group consisting of C 1 -C 12 alkyl
  • Q is selected from Q 1 or Q 2
  • R 8 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, difluoromethyl, pentafluoroethyl, heptafluoroisopropyl or cyclopropyl;
  • R 9 is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine or methyl;
  • R 8 is selected from the group consisting of difluoromethyl, R 9 is not hydrogen;
  • R 10 and R 11 are each independently selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, difluoromethyl, trifluoromethyl, pentafluoroethyl or heptafluoroisopropyl.
  • R 1 is selected from the group consisting of C 1 -C 3 alkyl
  • R 2 , R 3 , R 4 , R 5 are each independently selected from hydrogen;
  • R 6 is selected from the group consisting of C 1 -C 12 alkyl
  • Q is selected from Q 1 or Q 2
  • R 8 is selected from methyl or difluoromethyl
  • R 9 is selected from fluorine or chlorine
  • R 10 and R 11 are each independently selected from methyl, difluoromethyl, trifluoromethyl or cyclopropyl.
  • R 1 is selected from the group consisting of C 1 -C 3 alkyl
  • R 2 , R 3 , R 4 , R 5 are each independently selected from hydrogen;
  • R 6 is selected from C 1 -C 6 alkyl
  • Q is selected from Q 1 or Q 2
  • R 8 is selected from methyl or difluoromethyl
  • R 9 is selected from fluorine or chlorine
  • R 10 and R 11 are each independently selected from methyl, difluoromethyl, trifluoromethyl or cyclopropyl.
  • Alkyl means a straight or branched form such as methyl, ethyl, n-propyl, isopropyl and the like.
  • the haloalkyl group means a group in which an alkyl group is substituted by one or more halogen atoms, such as chloroethyl, trifluoromethyl, difluoromethyl, heptafluoroisopropyl and the like.
  • the cycloalkyl group includes a cyclopropyl group, a cyclobutyl group, a cyclopropylmethyl group, a methylcyclopropyl group and the like.
  • the alkenyl group means a linear or branched alkenyl group such as a 1-propenyl group, a 2-propenyl group or the like.
  • An alkynyl group means a straight or branched alkynyl group such as 1-propynyl, 2-propynyl and the like.
  • the alkoxy group means a group having an oxygen atom bonded to the terminal of the alkyl group, such as a methoxy group, an ethoxy group, a n-propoxy group, an isopropoxy group or the like.
  • Halogen means fluorine, chlorine, bromine or iodine.
  • the technical features of the present invention also include a method for preparing an amide compound (as shown in Formula I), and the groups in the reaction formula are as defined above unless otherwise noted.
  • the compound of the formula II is reacted with a compound of the formula III in a suitable solvent at a temperature of from -10 ° C to the boiling point of a suitable solvent for 0.5 to 48 hours to obtain the object compound I.
  • Suitable solvents are selected from the group consisting of dichloromethane, chloroform, carbon tetrachloride, hexane, benzene, toluene, ethyl acetate, acetonitrile, tetrahydrofuran, dioxane, N,N-dimethylformamide or dimethyl Sulfone and the like.
  • Suitable bases include alkali metals such as lithium, sodium or potassium hydrogen compounds such as sodium hydride, alkali metals such as lithium, sodium or potassium hydroxides such as sodium hydroxide, and alkali metal.
  • a carbonate such as sodium carbonate may also be an organic base such as triethylamine, sodium t-butoxide or the like.
  • the compound of formula II can be prepared by reference to the following literature: CN101979375A.
  • the compound of formula II can be prepared by reference to the following literature: CN1043127A.
  • L represents a leaving group and X represents a halogen.
  • the compound V can be obtained by reacting a compound of the formula II with a compound of the formula IV (commercially available) in a suitable solvent in the presence of a suitable base at a temperature of from -10 ° C to the boiling point of a suitable solvent for 0.5 to 48 hours.
  • Suitable solvents are selected from the group consisting of dichloromethane, chloroform, carbon tetrachloride, hexane, benzene, toluene, ethyl acetate, acetonitrile, tetrahydrofuran, dioxane, N,N-dimethylformamide or dimethyl Sulfone and the like.
  • Suitable bases include alkali metals such as lithium, sodium or potassium hydrogen compounds such as sodium hydride, alkali metals such as lithium, sodium or potassium hydroxides such as sodium hydroxide, and also alkali metal carbonates such as sodium carbonate. It may be an organic base such as triethylamine, sodium t-butoxide or the like.
  • the compound of the formula V is reacted with a compound of the formula VI (commercially available) in a suitable solvent in the presence of a suitable base at a temperature of from -10 ° C to the boiling point of a suitable solvent for 0.5 to 48 hours.
  • Suitable solvents are selected from the group consisting of dichloromethane, chloroform, carbon tetrachloride, hexane, benzene, toluene, ethyl acetate, acetonitrile, tetrahydrofuran, dioxane, N,N-dimethylformamide or dimethyl Sulfone and the like.
  • Suitable bases include alkali metals such as lithium, sodium or potassium hydrogen compounds such as sodium hydride, alkali metals such as lithium, sodium or potassium hydroxides such as sodium hydroxide, and also alkali metal carbonates such as sodium carbonate. It may be an organic base such as triethylamine, sodium t-butoxide or the like.
  • the compound of formula IV is a commercially available reagent.
  • Typical compounds of the amide compound of the formula I are listed in Tables 1 to 3, which may be used to further illustrate the invention, but are not intended to limit the invention.
  • "Me” represents a methyl group
  • "Et” represents an ethyl group
  • "n-Pr” represents a n-propyl group
  • "i-Pr” represents an isopropyl group
  • "cyc-Pr” represents a cyclopropyl group
  • n-Bu represents an "n-Bu” group.
  • Table 1 lists the structural and physical properties of a portion of a compound of formula I wherein Q is selected from Q 1 and R 2 , R 3 , R 4 , R 5 are each selected from hydrogen.
  • Table 2 lists the structural and physical properties of a portion of the compounds of formula I wherein Q is selected from Q 1 and R 2 and R 3 are each selected from hydrogen.
  • Table 3 shows the structure and physical properties of the compound moiety of the formula I, wherein Q is selected from Q 2, R 2, R 3 , R 4, R 5 are independently selected from hydrogen.
  • Me n-Pr CF 3 Et 87 Me n-Pr CF 3 i-Pr 88 Me n-Pr CF 3 n-Pr 89 Me n-Pr CF 3 CF 3 90 Me n-Pr CF 3 CF 2 H 91 Me n-Pr CF 2 H Me 92 Me n-Pr CF 2 H CF 2 H 93 Me n-Bu Me Me Me 94 Me n-Bu CF 3 Me White solid (65-67) 95 Me n-Bu CF 3 Et 96 Me n-Bu CF 3 i-Pr 97 Me n-Bu CF 3 n-Pr 98 Me n-Bu CF 3 CF 3 99 Me n-Bu CF 3 CF 2 H 100 Me n-Bu CF 2 H Me Red oil 101 Me H Me Me Me Me 102 Me H CF 3 Me Yellow solid (95-96) 103 Me H CF 3 Et 104 Me H CF 3 i-Pr 105 Me H CF
  • Compound 8 7.58 (d, 1H), 7.32 to 7.33 (m, 1H), 7.15 (t, 1H), 6.70 (d, 1H), 4.30 to 4.40 (m, 1H), 3.74 (s, 3H), 2.49 (s, 3H), 2.16 (s, 3H), 1.23 to 2.05 (m, 6H), 1.27 (d, 3H), 0.91 (t, 3H).
  • Compound 12 7.58 (s, 1H), 7.52 (d, 1H), 7.15 (t, 1H), 7.05 (t, 1H), 6.72 (d, 1H), 4.15 to 4.21 (m, 1H), 3.85 (s) , 3H), 2.16 (s, 3H), 1.50 to 1.80 (m, 2H), 1.27 to 1.50 (m, 4H), 1.28 (d, 3H), 0.93 (t, 3H).
  • Compound 17 7.59 (d, 1H), 7.31 to 7.33 (m, 1H), 7.15 (t, 1H), 6.70 (d, 1H), 4.30 to 4.40 (m, 1H), 3.75 (s, 3H), 2.49 (s, 3H), 2.16 (s, 3H), 1.27 to 1.80 (m, 8H), 1.28 (d, 3H), 0.89 (t, 3H).
  • Compound 26 7.58 (d, 1H), 7.31 to 7.33 (m, 1H), 7.15 (t, 1H), 6.70 (d, 1H), 4.30 to 4.40 (m, 1H), 3.74 (s, 3H), 2.49 (s, 3H), 2.16 (s, 3H), 1.27 to 1.80 (m, 10H), 1.28 (d, 3H), 0.88 (t, 3H).
  • Compound 27 7.87 (s, 1H), 7.55 (d, 1H), 7.16 (t, 1H), 7.13 to 7.18 (s, 1H), 6.73 (d, 1H), 4.32 to 4.38 (m, 1H), 3.94 (s, 3H), 2.19 (s, 3H), 1.29 (d, 3H), 1.23 to 1.80 (m, 10H), 0.90 (t, 3H).
  • Compound 33 7.87 (s, 1H), 7.53 (d, 1H), 7.15 (t, 1H), 7.13 to 7.18 (s, 1H), 6.71 (d, 1H), 4.18 to 4.21 (m, 1H), 3.94 (s, 3H), 2.19 (s, 3H), 1.61 to 2.04 (m, 4H), 1.26 to 1.42 (m, 4H), 0.95 (t, 3H), 0.90 (t, 3H).
  • Compound 42 7.60 (s, 1H), 7.58 (d, 1H), 7.11 (t, 1H), 7.03 (t, 1H), 6.54 (d, 1H), 4.58 to 4.60 (m, 1H), 4.19 (q) , 2H), 3.83 (s, 3H), 2.25 (s, 3H), 1.93 to 2.03 (m, 2H), 1.47 to 1.54 (m, 2H), 1.24 (t, 3H), 1.21 to 1.37 (m, 6H) ), 0.88 (t, 3H).
  • the amide compound of the present invention has unexpectedly high bactericidal activity compared to known amide compounds. Accordingly, the present invention also encompasses the use of a compound of formula I for controlling diseases for the control of Oomycetes, Ascomycetes, Basidiomycetes, Deuteromycetes, and swollen roots. Plasmodiophoromycetes, Chytridiomycetes, and Zygomycetes diseases.
  • the present invention also encompasses a bactericidal composition having a compound of the formula I as an active ingredient.
  • the compound of the formula I as an active ingredient in the bactericidal composition is present in an amount of from 1 to 99% by weight.
  • an agriculturally acceptable carrier is also included in the germicidal composition.
  • compositions of the invention may be administered in the form of a formulation.
  • the amide compound (as shown in Formula I) is dissolved or dispersed as an active ingredient in a carrier or formulated to be a composition which is easier to disperse when used as a sterilizing agent.
  • these chemicals can be formulated as wettable powders or emulsifiable concentrates.
  • at least one liquid or solid carrier is added, and a suitable surfactant may be added as needed.
  • the technical solution of the present invention further includes a method for controlling a disease by applying the above-mentioned bactericidal composition of the present invention to the disease or its growth medium.
  • a more suitable effective amount is usually selected from 10 grams to 1000 grams per hectare.
  • one or more other insecticides, bactericides, herbicides, plant growth regulators or fertilizers may be added to the germicidal compositions of the invention, thereby producing additional Advantages and effects.
  • test method is as follows:
  • the living body potting method is used, that is, the sample of the test compound is selected with a small amount of solvent (the kind of the solvent such as acetone, methanol, DMF, etc., according to the solvency of the sample, and the volume ratio of the amount of the solvent to the amount of the sprayed liquid is equal to or less than 0.05.
  • Foliar spray treatment was carried out at a designed concentration with the compounds of the invention. A blank control of sprayed water was also set up, repeated 3 times, and the disease was inoculated the next day after the treatment.
  • the plants were placed in an artificial climate chamber for moisturizing culture (temperature: ⁇ 25 ° C, night 20 ° C, relative humidity: 95-99%).
  • moisturizing culture temperature: ⁇ 25 ° C, night 20 ° C, relative humidity: 95-99%.
  • the greenhouse culture was transplanted, and plants which did not require moisturizing culture were directly inoculated and cultured in a greenhouse.
  • the compound disease prevention effect evaluation was performed after the control was sufficiently ill (usually one week).
  • the results of the survey refer to the "A Manual of Assessment Keys for Plant Diseases" prepared by the American Plant Disease Society, which is represented by 100 to 0.
  • the "100" level represents disease-free and the "0" level represents the most serious disease.
  • the following compounds have better control effect at a concentration of 400 ppm, and the control effect is ⁇ 80%: compounds 2, 4, 11, 13, 36, 70, 71, 102, 110 and 111 .
  • the compounds 2 , 4 , 11 , 13 , 71 and 111 of the present invention are selected in parallel with the known compounds KC 1 , KC 2 , KC 3 , KC 4 , KC 5 and KC 6 for controlling the downy mildew activity of cucumber.
  • the determination control compounds are all self-made, and the structure is confirmed by nuclear magnetic resonance spectroscopy as described in the existing publication), and the test results are shown in Table 2.
  • the following compounds have better control effect on corn rust at a concentration of 400 ppm, and the control effect is ⁇ 80%: compounds 2, 4, 11, 13, 71, 72, 102, 109 , 110, 111 and 112.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明属于杀菌剂领域。涉及一种酰胺类化合物及其制备方法和用途。酰胺类化合物如通式I所示：通式I中各取代基定义见说明书。本发明通式I化合物具有优异的杀菌活性，可用于防治真菌病害。

Description

一种酰胺类化合物及其制备方法和用途 技术领域
本发明属于杀菌剂领域。涉及一种酰胺类化合物及其制备方法和用途。
背景技术
由于杀菌剂在使用一段时间后，病害会对其产生抗性，因此，需要不断发明新型的和改进的具有杀菌活性的化合物和组合物。
吡唑酰胺及噻唑酰胺化合物的杀菌活性已有报道。如JP62249975公开了吡唑酰胺类化合物KC1、KC2、KC3和KC4(分别为专利中化合物3、2、10和4)及其杀菌活性。JP5657776公开了噻唑酰胺化合物KC5(专利中化合物1)及其杀菌活性。Pesticide Science(1993),38(1),1-7公开了噻唑酰胺类化合物KC6(文章中化合物XIV)及其杀菌活性。
Figure PCTCN2016080952-appb-000001
现有技术中，结构如本发明通式I所示的酰胺类化合物未见报道。
发明内容
本发明的目的在于提供一种杀菌活性更好的酰胺类化合物，它可应用于农业、林业上病害的防治。
为实现上述目的，本发明的技术方案如下：
本发明提供了酰胺类化合物，如通式I所示：
Figure PCTCN2016080952-appb-000002
式中：
R1、R2、R3、R4、R5、R6分别独立地选自氢、卤素、氰基、C1～C12的烷基、C1～C12的烷氧基、C1～C12的卤代烷基、C3～C6的环烷基、C3～C6的卤代环烷基、C2～C6的烯基、C2～C6的炔基、羟基-C1～C6的烷基、C1～C6的烷氧基-C1～C6的烷基、C3～C6的环烷基-C1～C6的烷基氧基-C1～C6的烷基、C1～C6的卤代烷氧基-C1～C6的烷基、C3～C8烯基氧基-C1～C6的烷基、C3～C8炔基氧基-C1～C6的烷基、芳基-C1～C6的烷氧基-C1～C6的烷基、C1～C6的烷氧基羰基、C1～C6的卤代烷氧羰基、C3～C6的环烷氧基羰基、C3～C6的卤代环烷氧羰基、C3～C6的环烷基-C1～C6的烷氧基羰基、芳基氧羰基、C1～C6的烷基胺基羰基、C3～C6的环烷胺基羰基、C3～C6的环烷基-C1～C6的烷胺基羰基、芳基胺基羰基、芳基-C1～C6的烷胺基羰基，以及上述芳基-C1～C6的烷氧基-C1～C6的烷基、芳基氧羰基、芳基胺基羰基、芳基-C1～C6的烷胺基羰基中芳基被至多6个(1-6)相同或不同的R7取代后的基团；
其中芳基选自苯环、具有1～3个杂原子的5或6元杂环或苯并具有1～3个杂原子的5或6元杂环；
R7选自卤素、硝基、氰基、C1～C6的烷基或C1～C6的卤代烷基；
Q选自Q1或Q2
Figure PCTCN2016080952-appb-000003
R8选自C1～C3的烷基、C1～C3的卤代烷基或C3～C6的环烷基；
R9选自氢、卤素或甲基；
其中，当R8选自二氟甲基时，R9不为氢；
R10和R11分别独立地选自C1～C6的烷基、C1～C6的卤代烷基或C3～C6的环烷基。
本发明中优选的技术方案为，通式I中：
R1、R2、R3、R4、R5、R6分别独立地选自氢、卤素、氰基、C1～C12的烷基、C1～C6的烷氧基、C1～C6的卤代烷基、C3～C6的环烷基、C3～C6的卤代环烷基、C2～C6的烯基、C2～C6的炔基、羟基-C1～C3的烷基、C1～C3的烷氧基-C1～C3的烷基、C3～C6的环烷基-C1～C3的烷基氧基-C1～C3的烷基、C1～C3的卤代烷氧基-C1～C3的烷基、C3～C6烯基氧基-C1～C3的烷基、C3～C6炔基氧基-C1～C6的烷基、芳基-C1～C3的烷氧基-C1～C3的烷基、C1～C3的烷氧基羰基、C1～C3的卤代烷氧羰基、C3～C6的环烷氧基羰基、C3～C6的卤代环烷氧羰基、C3～C6的环烷基-C1～C3的烷氧基羰基、芳基氧羰基、C1～C3的烷基胺基羰基、C3～C6的环烷胺基羰基、C3～C6的环烷基-C1～C3的烷胺基羰基、芳基胺基羰基、芳基-C1～C3的烷胺基羰基，以及上述芳基-C1～C6的烷氧基-C1～C6的烷基、芳基氧羰基、芳基胺基羰基、芳基-C1～C6的烷胺基羰基中芳基被至多6个相同或不同的R7取代后的基团；
其中为芳基选自苯环、具有1～3个杂原子的5或6元杂环或苯并具有1～3个杂原子的5或6元杂环；
R7选自卤素、硝基、氰基、C1～C3的烷基或C1～C3的卤代烷基；
Q选自Q1或Q2
Figure PCTCN2016080952-appb-000004
R8选自C1～C3的烷基、C1～C3的卤代烷基或C3～C6的环烷基；
R9选自氢、卤素或甲基；
其中，当R8选自二氟甲基时，R9不为氢；
R10和R11分别独立地选自C1～C3的烷基、C1～C3的卤代烷基或C3～C6的环烷基。
本发明中进一步优选的技术方案为，通式I中：
R1、R2、R3、R4、R5、R6分别独立地选自氢、氟、氯、溴、碘、氰基、C1～C12的烷基、C1～C3的烷氧基、C1～C6的卤代烷基、C3～C6的环烷基、C3～C6的卤代环烷基、C2～C6的烯基、C2～C6的炔基、羟基-C1～C3的烷基、C1～C3的烷氧基-C1～C3的烷基、C3～C6的环烷基-C1～C3的烷基氧基-C1～C3的烷基、C1～C3的卤代烷氧基-C1～C3的烷基、C3～C6烯基氧基-C1～C3的烷基、C3～C6炔基氧基-C1～C6的烷基、芳基-C1～C3的烷氧基-C1～C3的烷基、C1～C3的烷氧基羰基、C1～C3的卤代烷氧羰基、C3～C6的环烷氧基羰基、C3～C6的卤代环烷氧羰基、C3～C6的环烷基-C1～C3的烷氧基羰基、芳基氧羰基、C1～C3的烷基胺基羰基、C3～C6的环烷胺基羰基、C3～C6的环烷基-C1～C3的烷胺基羰基、芳基胺基羰基、芳基-C1～C3的烷胺基羰基，以及上述芳基-C1～C6的烷氧基-C1～C6的烷基、芳基氧羰基、 芳基胺基羰基、芳基-C1～C6的烷胺基羰基中芳基被至多6个相同或不同的R7取代后的基团；
其中为芳基选自苯环、呋喃、噻吩、吡咯、吡唑、噁唑、异噁唑、噻唑基、吡啶、吡嗪、嘧啶、哒嗪、苯并噁唑、苯并噻唑、喹喔啉或喹唑啉基；
R7选自氟、氯、溴、碘、硝基、氰基、C1～C3的烷基或C1～C3的卤代烷基；
Q选自Q1或Q2
Figure PCTCN2016080952-appb-000005
R8选自C1～C3的烷基、C1～C3的卤代烷基或C3～C6的环烷基；
R9选自氢、卤素或甲基；
其中，当R8选自二氟甲基时，R9不为氢；
R10和R11分别独立地选自C1～C3的烷基、C1～C3的卤代烷基或C3～C6的环烷基。
本发明中更进一步优选的技术方案为，通式I中：
R1选自氟、C1～C3的烷基或C1～C3的卤代烷基；
R2、R3、R4、R5分别独立地选自氢、氟、C1～C3的烷基或C1～C3的卤代烷基；
R6选自C1～C12的烷基；
Q选自Q1或Q2
Figure PCTCN2016080952-appb-000006
R8选自甲基、乙基、正丙基、异丙基、三氟甲基、二氟甲基、五氟乙基、七氟异丙基或环丙基；
R9选自氢、氟、氯、溴、碘或甲基；
其中，当R8选自二氟甲基时，R9不为氢；
R10和R11分别独立地选自甲基、乙基、丙基、异丙基、环丙基、二氟甲基、三氟甲基、五氟乙基或七氟异丙基。
本发明中特别优选的技术方案为，通式I中：
R1选自C1～C3的烷基；
R2、R3、R4、R5分别独立地选自氢；
R6选自C1～C12的烷基；
Q选自Q1或Q2
Figure PCTCN2016080952-appb-000007
R8选自甲基或二氟甲基；
R9选自氟或氯；
R10和R11分别独立地选自甲基、二氟甲基、三氟甲基或环丙基。
本发明中特别优选的技术方案为，通式I中：
R1选自C1～C3的烷基；
R2、R3、R4、R5分别独立地选自氢；
R6选自C1～C6的烷基；
Q选自Q1或Q2
Figure PCTCN2016080952-appb-000008
R8选自甲基或二氟甲基；
R9选自氟或氯；
R10和R11分别独立地选自甲基、二氟甲基、三氟甲基或环丙基。
上面给出的通式I化合物的定义中，汇集所用术语一般定义如下：
烷基是指直链或支链形式，例如甲基、乙基、正丙基、异丙基等。卤代烷基是指烷基被一个或多个卤原子取代的基团，如氯乙基、三氟甲基、二氟甲基、七氟异丙基等。环烷基包括环丙基、环丁基、环丙基甲基、甲基环丙基等。烯基是指直链或支链烯基，如1-丙烯基、2-丙烯基等。炔基是指直链或支链炔基，如1-丙炔基、2-丙炔基等。烷氧基是指烷基末端连有氧原子的基团，例如甲氧基、乙氧基、正丙氧基、异丙氧基等。卤素是指氟、氯、溴、碘。
本发明技术特征还包括酰胺类化合物(如通式I所示)的制备方法，除另有注明外，反应式中各基团定义同前。
方法一：
Figure PCTCN2016080952-appb-000009
通式II化合物与通式III化合物在适宜的溶剂中，温度为-10℃到适宜溶剂的沸点下反应0.5-48小时制得目标化合物I。
适宜的溶剂选自二氯甲烷、氯仿、四氯化碳、己烷、苯、甲苯、乙酸乙酯、乙腈、四氢呋喃、二氧六环、N,N-二甲基甲酰胺或二甲基亚砜等。
加入适宜的碱对反应有利，适宜的碱包括碱金属如锂、钠或钾的氢化合物如氢化钠，碱金属如锂、钠或钾的氢氧化物如氢氧化钠，还可以是碱金属的碳酸盐如碳酸钠，也可以是有机碱如三乙胺、叔丁醇钠等。
当Q选自Q1时，可参考下列文献制备通式II化合物：CN101979375A。当Q选自Q2时，可参考下列文献制备通式II化合物：CN1043127A。
通式III化合物可参考下列文献制备：Bioorganic&Medicinal Chemistry,2012，20(3):1213-1221；农药，2007,46(5):307-309。
方法二：
Figure PCTCN2016080952-appb-000010
式中，L代表离去基团、X代表卤素。
通式II化合物与通式IV化合物(市售)在适宜的溶剂中、适宜的碱存在下，温度为-10℃到适宜溶剂的沸点下反应0.5-48小时制得化合物V。
适宜的溶剂选自二氯甲烷、氯仿、四氯化碳、己烷、苯、甲苯、乙酸乙酯、乙腈、四氢呋喃、二氧六环、N,N-二甲基甲酰胺或二甲基亚砜等。
适宜的碱包括碱金属如锂、钠或钾的氢化合物如氢化钠，碱金属如锂、钠或钾的氢氧化物如氢氧化钠，还可以是碱金属的碳酸盐如碳酸钠，也可以是有机碱如三乙胺、叔丁醇钠等。
通式V化合物与通式VI化合物(市售)在适宜的溶剂中、适宜的碱存在下，温度为-10℃到适宜溶剂的沸点下反应0.5-48小时制得目标物化合物I。
适宜的溶剂选自二氯甲烷、氯仿、四氯化碳、己烷、苯、甲苯、乙酸乙酯、乙腈、四氢呋喃、二氧六环、N,N-二甲基甲酰胺或二甲基亚砜等。
适宜的碱包括碱金属如锂、钠或钾的氢化合物如氢化钠，碱金属如锂、钠或钾的氢氧化物如氢氧化钠，还可以是碱金属的碳酸盐如碳酸钠，也可以是有机碱如三乙胺、叔丁醇钠等。
通式IV化合物为市售试剂。
作为通式I酰胺类化合物典型化合物列在表1至表3中，可用来进一步说明本发明，但不意味着限制本发明。“Me”表示甲基，“Et”表示乙基，“n-Pr”表示正丙基，“i-Pr”表示异丙基，“cyc-Pr”表示环丙基，“n-Bu”表示正丁基
表1列出了部分通式I化合物的结构和物理性质，其中Q选自Q1，R2、R3、R4、R5分别选自氢。
Figure PCTCN2016080952-appb-000011
表1部分通式I化合物的结构和物理性质
Figure PCTCN2016080952-appb-000012
Figure PCTCN2016080952-appb-000013
Figure PCTCN2016080952-appb-000014
表2列出了部分通式I化合物的结构和物理性质，其中Q选自Q1，R2、R3分别选自氢。
Figure PCTCN2016080952-appb-000015
Figure PCTCN2016080952-appb-000016
表3列出了部分通式I化合物的结构和物理性质，其中Q选自Q2，R2、R3、R4、R5分别选自氢。
Figure PCTCN2016080952-appb-000017
序号 R1 R6 R10 R11 外观(熔点(℃))
66 Me Et Me Me 黄色液体
67 Me Et Et Me 黄色液体
68 Me Et i-Pr Me  
69 Me Et cyc-Pr Me  
70 Me Et Me CF3 黄色固体(70-71)
71 Me Et CF3 Me 黄色液体
72 Me Et CF3 Et  
73 Me Et CF3 i-Pr  
74 Me Et CF3 n-Pr  
75 Me Et CF3 CF3  
76 Me Et CF3 CF2H  
77 Me Et CF2H Me 黄色液体
78 Me Et CF2H CF3  
79 Me Et CF2H CF2H  
80 Me n-Pr Me Me  
81 Me n-Pr Et Me  
82 Me n-Pr i-Pr Me  
83 Me n-Pr cyc-Pr Me  
84 Me n-Pr Me CF3 黄色液体
85 Me n-Pr CF3 Me 黄色液体
86 Me n-Pr CF3 Et  
87 Me n-Pr CF3 i-Pr  
88 Me n-Pr CF3 n-Pr  
89 Me n-Pr CF3 CF3  
90 Me n-Pr CF3 CF2H  
91 Me n-Pr CF2H Me  
92 Me n-Pr CF2H CF2H  
93 Me n-Bu Me Me  
94 Me n-Bu CF3 Me 白色固体(65-67)
95 Me n-Bu CF3 Et  
96 Me n-Bu CF3 i-Pr  
97 Me n-Bu CF3 n-Pr  
98 Me n-Bu CF3 CF3  
99 Me n-Bu CF3 CF2H  
100 Me n-Bu CF2H Me 红色油
101 Me H Me Me  
102 Me H CF3 Me 黄色固体(95-96)
103 Me H CF3 Et  
104 Me H CF3 i-Pr  
105 Me H CF3 n-Pr  
106 Me H CF3 CF3  
107 Me H CF3 CF2H  
108 Me H CF2H Me  
109 Me Me Me Me 黄色油
110 Me Me Et Me 黄色油
111 Me Me Et CF3 黄色油
112 Me Me CF3 Me 黄色固体(70-71)
113 Me Me CF3 Et  
114 Me Me CF3 i-Pr  
115 Me Me CF3 n-Pr  
116 Me Me CF3 CF3  
117 Me Me CF3 CF2H  
118 Me Me CF2H Me  
部分化合物的1H NMR(300MHz,CDCl3)数据如下：
化合物2:7.70(s,1H),7.47(d,1H),7.15-7.18(m,2H),6.70(d,1H),4.35-4.38(m,1H),3.89(s,3H),3.45-3.55(m,1H),2.16(s,3H),1.56-1.75(m,2H),1.28-1.46(m,13H),0.88-0.96(m,3H)。
化合物4:7.72(s,1H),7.59(d,1H),7.17(t,1H),6.71(d,1H),4.33-4.40(m,1H),3.84(s,3H),2.52(s,3H),2.19(s,3H),1.57-1.80(m,2H),1.26-1.47(m,7H),0.88-0.97(m,3H)。
化合物5:7.73(s,1H),7.58(d,1H),7.16(t,1H),6.71(d,1H),4.30～4.40(m,1H),3.86(s,3H),2.96(q,2H),2.20(s,3H),1.25～1.80(m,6H),1.29(d,3H),1.28(t,3H),0.91(t,3H)。
化合物8:7.58(d,1H),7.32～7.33(m,1H),7.15(t,1H),6.70(d,1H),4.30～4.40(m,1H),3.74(s,3H),2.49(s,3H),2.16(s,3H),1.23～2.05(m,6H),1.27(d,3H),0.91(t,3H)。
化合物11:7.89(s,1H),7.58(d,1H),7.21(t,1H),7.19(t,1H),6.76(d,1H),4.38-4.42(m,1H),3.99(s,3H),2.22(s,3H),1.60-1.80(m,2H),1.32-1.47(m,7H),0.94-1.00(m,3H)。
化合物12:7.58(s,1H),7.52(d,1H),7.15(t,1H),7.05(t,1H),6.72(d,1H),4.15～4.21(m,1H),3.85(s,3H),2.16(s,3H),1.50～1.80(m,2H),1.27～1.50(m,4H),1.28(d,3H),0.93(t,3H)。
化合物13:8.02(s,1H),7.61(s,1H),7.45(d,1H),7.15(t,1H),6.73(d,1H),4.31-4.36(m,1H),3.97(s,3H),2.15(s,3H),1.56-1.75(m,2H),1.28-1.44(m,7H),0.91-0.94(m,3H)。
化合物15:7.72(s,1H),7.59(d,1H),7.16(t,1H),6.70(d,1H),4.32-4.36(m,1H),3.85(s,3H),2.52(s,3H),2.19(s,3H),1.65-1.79(m,2H),1.27-1.58(m,9H),0.86-0.94(m,3H)。
化合物16:7.73(s,1H),7.58(d,1H),7.16(t,1H),6.71(d,1H),4.30～4.40(m,1H),3.86(s,3H),2.96(q,2H),2.20(s,3H),1.25～1.80(m,8H),1.29(d,3H),1.28(t,3H),0.89(t,3H)。
化合物17:7.59(d,1H),7.31～7.33(m,1H),7.15(t,1H),6.70(d,1H),4.30～4.40(m,1H),3.75(s,3H),2.49(s,3H),2.16(s,3H),1.27～1.80(m,8H),1.28(d,3H),0.89(t,3H)。
化合物18:7.87(s,1H),7.54(d,1H),7.15(t,1H),7.12～7.17(m,1H),6.72(d,1H),4.32～4.38(m,1H),3.93(s,3H),2.18(s,3H),1.32(d,3H),1.23～2.03(m,8H),0.89(t,3H)。
化合物19:7.58(s,1H),7.52(d,1H),7.14(t,1H),7.05(t,1H),6.72(d,1H),4.32～4.38(m,1H),3.83(s,3H),2.18(s,3H),1.31～1.76(m,8H),1.28(d,3H),0.89(t,3H)。
化合物22:7.73(s,1H),7.60(d,1H),7.16(t,1H),6.71(d,1H),4.32-4.36(m,1H),3.85(s,3H),2.52(s,3H),2.20(s,3H),1.60-1.74(m,2H),1.27-1.61(m,11H),0.86-0.94(m,3H)。
化合物23:7.72(s,1H),7.58(d,1H),7.16(t,1H),6.71(d,1H),4.30～4.40(m,1H),3.86(s,3H),2.96(q,2H),2.20(s,3H),1.25～1.80(m,10H),1.29(d,3H),1.28(t,3H),0.88(t,3H)。
化合物26:7.58(d,1H),7.31～7.33(m,1H),7.15(t,1H),6.70(d,1H),4.30～4.40(m,1H),3.74(s,3H),2.49(s,3H),2.16(s,3H),1.27～1.80(m,10H),1.28(d,3H),0.88(t,3H)。
化合物27:7.87(s,1H),7.55(d,1H),7.16(t,1H),7.13～7.18(s,1H),6.73(d,1H),4.32～4.38(m,1H),3.94(s,3H),2.19(s,3H),1.29(d,3H),1.23～1.80(m,10H),0.90(t,3H)。
化合物28:7.57(s,1H),7.53(d,1H),7.15(t,1H),7.05(t,1H),6.72(d,1H),4.34～4.36(m,1H),3.85(s,3H),2.16(s,3H),1.28(d,3H),1.23～1.60(m,10H),0.88(t,3H)
化合物29:8.04(s,1H),7.58(s,1H),7.46(d,1H),7.17(t,1H),6.73(d,1H),4.32-4.36(m,1H),3.99(s,3H),2.15(s,3H),1.65-1.79(m,2H),1.23-1.61(m,11H),0.86-0.90(m,3H)。
化合物30:7.53-7.56(m,2H),7.17(t,1H),6.73(d,1H),4.32-4.36(m,1H),3.96(s,3H),2.16(s,3H),1.65-1.79(m,2H),1.27-1.58(m,11H),0.86-0.90(m,3H)。
化合物31:7.73(s,1H),7.58(d,1H),7.15(t,1H),6.69(d,1H),4.17-4.21(m,1H),3.85(s,3H),2.46(s,3H),2.21(s,3H),1.63-1.70(m,4H),1.28-1.36(m,4H),0.87-0.97(m,6H)。
化合物33:7.87(s,1H),7.53(d,1H),7.15(t,1H),7.13～7.18(s,1H),6.71(d,1H),4.18～4.21(m,1H),3.94(s,3H),2.19(s,3H),1.61～2.04(m,4H),1.26～1.42(m,4H),0.95(t,3H),0.90(t,3H)。
化合物34:7.59(s,1H),7.50(d,1H),7.14(t,1H),7.05(t,1H),6.70(d,1H),4.18～4.20(m,1H),3.83(s,3H),2.19(s,3H),1.64～1.70(m,4H),1.27～1.38(m,4H),0.95(t,3H),0.90(t,3H)
化合物35:8.04(s,1H),7.58(s,1H),7.46(d,1H),7.15(t,1H),6.71(d,1H),4.17-4.21(m,1H),3.99(s,3H),2.16(s,3H),1.63-1.70(m,4H),1.26-1.38(m,4H),0.87-0.97(m,6H)。
化合物36:7.54-7.61(m,2H),7.15(t,1H),6.71(d,1H),4.17-4.21(m,1H),3.96(s,3H),2.17(s,3H),1.63-1.72(m,4H),1.28-1.41(m,4H),0.83-0.97(m,6H)。
化合物41:7.89(s,1H),7.59(d,1H),7.10(t,1H),7.08～7.13(m,1H),6.54(d,1H),4.58～4.62(m,1H),4.18(q,2H),3.91(s,3H),2.25(s,3H),1.93～1.98(m,2H),1.47～1.54(m,2H),1.23(t,3H),1.21～1.37(m,6H),0.87(t,3H)。
化合物42:7.60(s,1H),7.58(d,1H),7.11(t,1H),7.03(t,1H),6.54(d,1H),4.58～4.60(m,1H),4.19(q,2H),3.83(s,3H),2.25(s,3H),1.93～2.03(m,2H),1.47～1.54(m,2H),1.24(t,3H),1.21～1.37(m,6H),0.88(t,3H)。
化合物66：7.44(d,1H),7.28(s,1H),7.13-7.18(t,1H),6.73(d,1H),4.32-4.36(m,1H),2.72(s,3H),2.70(s,3H),2.15(s,3H),1.57-1.79(m,2H),1.21-1.48(m,7H),0.88-0.97(m,3H)。
化合物67：7.46(d,1H),7.25(s,1H),7.13-7.18(t,1H),6.72(d,1H),4.32-4.36(m,1H),3.07-3.14(m,2H),2.72(s,3H),2.15(s,3H),1.55-1.79(m,2H),1.21-1.47(m,10H),0.88-0.96(m,3H)。
化合物70：7.38-7.41(m,2H),7.16-7.20(t,1H),6.77(d,1H),4.33-4.41(m,1H),2.82(s,3H),2.18(s,3H),1.58-1.76(m,2H),1.29-1.42(m,7H),0.90-0.97(m,3H)。
化合物71：7.66(s,1H),7.43(d,1H),7.14-7.17(t，1H),6.76(d,1H),4.35-4.37(m,1H),2.76(s,3H),2.15(s,3H),1.60-1.76(m,2H),1.29-1.44(m,7H),0.91-0.94(m,3H)。
化合物77：7.76(s,1H),7.38(d,1H),7.20(t,1H),7.13-7.18(t,1H),6.75(d,1H),4.32-4.36(m,1H),2.76(s,3H),2.15(s,3H),1.57-1.79(m,2H),1.21-1.48(m,7H),0.88-0.97(m,3H)。
化合物84：7.44(s,1H),7.39(d,1H),7.16-7.20(t,1H),6.77(d,1H),4.33-4.41(m,1H),2.82(s,3H),2.17(s,3H),1.61-1.79(m,2H),1.21-1.42(m,9H),0.87-0.95(m,3H)。
化合物85：7.63(s,1H),7.44(d,1H),7.14-7.18(t,1H),6.76(d,1H),4.32-4.36(m,1H),2.76(s,3H),2.15(s,3H),1.69-1.79(m,2H),1.21-1.48(m,9H),0.86-0.91(m,3H)。
化合物94：7.74(s,1H),7.41(d,1H),7.02-7.38(t,1H),7.14-7.17(d,1H),6.74-6.77(d,1H),4.33-4.37(m,1H),2.77(s,3H),2.16(s,3H),1.73-1.81(m,2H),1.31-1.45(m,8H),1.28-1.30(d,3H),0.86-0.92(m,3H)。
化合物100：7.65(s,1H),7.44(d,1H),7.16-7.20(t,1H),6.75-6.77(d,1H),4.35-4.37(m,1H),2.76(s,3H),2.15(s,3H),1.43-1.62(m,4H),1.31-1.42(m,6H),1.28-1.30(d,3H),0.86-0.91(m,3H)。
化合物102：7.63(s,1H),7.44-7.47(d,1H),7.14-7.20(t,1H),6.75-6.77(d,1H),4.28-4.34(m,1H),2.77(s,3H),2.16(s,3H),1.62-1.81(m,2H),1.28-1.30(d,3H),0.96-1.01(t,3H),0.86-0.91(m,3H)。
化合物109：7.42-7.44(d,1H),7.29(s,1H),7.13-7.18(t,1H),6.72-6.75(d,1H),4.36-4.38(m,1H),2.70(s,3H),2.73(s,3H),2.16(s,3H),1.40-1.74(m,4H),1.26-1.28(d,3H),0.92-0.96(t,3H),0.86-0.91(t,3H)。
化合物110：7.45-7.48(d,1H),7.25(s,1H),7.16-7.18(t,1H),6.72-6.74(d,1H),4.38-4.40(m,1H),3.01-3.12(q,2H),2.72(s,3H),2.16(s,3H),1.43-1.72(m,4H),1.28-1.36(m,6H),0.94-0.96(m,3H)。
化合物111：7.42(s,1H),7.37-7.40(d,1H),7.15-7.20(t,1H),6.76-6.79(d,1H),4.38-4.40(m,1H),3.12-3.20(q,2H),2.17(s,3H),1.44-1.77(m,4H),1.37-1.42(t,3H),1.31-1.35(d,3H),0.92-0.97(t,3H)。
化合物112：7.63(s,1H),7.44-7.46(d,1H),7.17-7.20(t,1H),6.76-6.78(d,1H),4.37-4.39(m,1H),2.76(s,3H),2.15(s,3H),1.40-1.73(m,4H),1.30-1.39(d,3H),0.92-0.97(t,3H)。
同已知的酰胺类化合物相比，本发明的酰胺类化合物具有意想不到的高杀菌活性。因此，本发明还包括通式I化合物用于控制病害的用途，以防治卵菌纲(Oomycetes)、子囊菌纲(Ascomycetes)、担子菌纲(Basidiomycetes)、半知菌纲(Deuteromycetes)、根肿菌纲(Plasmodiophoromycetes)、壶菌纲(Chytridiomycetes)和结合菌亚纲(Zygomycetes)病害。
在上面列出的纲名下的某些病害的实例可提及的包括但不限于：
小麦锈病、小麦白粉病、小麦赤霉病、小麦根腐病、小麦纹枯病、小麦全蚀病、小麦颖枯病、黄瓜霜霉病、黄瓜炭疽病、黄瓜枯萎病、黄瓜灰霉病、葡萄霜霉病、番茄早疫病、番茄晚疫病、水稻纹枯病、水稻稻瘟病、西瓜蔓枯病、花生疮痂病、花生黑斑病、柑橘疮痂病、辣椒根腐病、棉花黄萎病、棉花枯萎病、油菜黑茎病、油菜菌核病、梨黑星病、人参锈腐病、玉米锈病、玉米弯孢病、玉米大斑病、芒果蒂腐病、苹果轮纹病、苹果腐菌烂病、香蕉叶斑病。
本发明还包括以通式I化合物作为活性组分的杀菌组合物。该杀菌组合物中作为活性组分的通式I化合物的重量百分含量在1～99％之间。该杀菌组合物中还包括农业上可接受的载体。
本发明的组合物可以制剂的形式施用。酰胺类化合物(如通式I所示)作为活性组分溶解或分散于载体中或配制成制剂以便作为杀菌使用时更易于分散的组合物。例如：这些化学制剂可被制成可湿性粉剂或乳油。在这些组合物中，至少加入一种液体或固体载体，并且当需要时可以加入适当的表面活性剂。
本发明的技术方案还包括防治病害的方法：将本发明上述的杀菌组合物施于所述的病害或其生长介质上。通常选择的较为适宜的有效量为每公顷10克到1000克。
对于某些应用，例如在农业上可在本发明的杀菌组合物中加入一种或多种其它的杀虫剂、杀菌剂、除草剂、植物生长调节剂或肥料等，由此可产生附加的优点和效果。具体实施方式
下列合成实施例、生物活性测定实施例可用来进一步说明本发明，但不意味着限制本发明。
合成实施例
实施例1化合物28的合成
Figure PCTCN2016080952-appb-000018
反应瓶中加入2-甲基-3-(2-辛氧基)苯胺(240毫克，1.03毫摩尔)、三乙胺(110毫克，1.09毫摩尔)和10毫升二氯甲烷，室温搅拌下滴加1-甲基-3-二氟甲基-5-氟吡唑-4-甲酰氯(210毫克，0.99毫摩尔)的二氯甲烷溶液10毫升。滴毕，室温下反应，3小时后反应完毕。反应液倾入至30毫升水中，取有机层，有机层分别用饱和碳酸氢钠水溶液、饱和食盐水洗涤，无水硫酸镁干燥，减压蒸尽溶剂。残余物通过柱色谱提纯(淋洗液：乙酸乙酯：石油醚＝1：2)，得250毫克化合物28，收率60.8％。
实施例2化合物41的合成
Figure PCTCN2016080952-appb-000019
反应瓶中加入2-(2-甲基-3-氨基苯氧基)-辛酸乙酯(290毫克，0.99毫摩尔)、三乙胺(110毫克，1.09毫摩尔)和10毫升二氯甲烷，室温搅拌下滴加1-甲基-3-二氟甲基-5-氯吡唑-4-甲酰氯(230毫克，1.00毫摩尔)的二氯甲烷溶液10毫升。滴毕，室温下反应，3小时后反应完毕。反应液倾入至30毫升水中，取有机层，有机层分别用饱和碳酸氢钠水溶液、饱和食盐水洗涤，无水硫酸镁干燥，减压蒸尽溶剂。残余物通过柱色谱提纯(淋洗液：乙酸乙酯：石油醚＝1：2)，得190毫克化合物41，收率72.0％。
实施例3化合物70的制备：
Figure PCTCN2016080952-appb-000020
反应瓶中加入2-甲基-3-(2-己氧基)苯胺(230毫克，1.10毫摩尔)、三乙胺(140毫克，1.33毫摩尔)和10毫升二氯甲烷，室温搅拌下滴加2-三氟甲基-4-甲基噻唑-5-甲酰氯(310毫克，1.33毫摩尔)的二氯甲烷溶液10毫升。滴毕，室温下反应，2小时后反应完毕。反应液倾入至30毫升水中，取有机层，有机层依次用饱和碳酸氢钠水溶液、饱和食盐水洗涤，无水硫酸镁干燥，减压蒸尽溶剂。残余物通过柱色谱提纯(淋洗液：乙酸乙酯：石油醚＝1：8)，得150毫克化合物70，收率33.4％。
实施例4化合物71的制备：
Figure PCTCN2016080952-appb-000021
反应瓶中加入2-甲基-3-(2-己氧基)苯胺(200毫克，0.96毫摩尔)、三乙胺(120毫克，1.17毫摩尔)和10毫升二氯甲烷，室温搅拌下滴加2-甲基-4-三氟甲基噻唑-5-甲酰氯(270毫克，1.17毫摩尔)的二氯甲烷溶液10毫升。滴毕，室温下反应，2小时后反应完毕。反应液倾入30毫升水中，取有机层，有机层分别用饱和碳酸氢钠水溶液、饱和食盐水洗涤，无水硫酸镁干燥，减压蒸尽溶剂。残余物通过柱色谱提纯(淋洗液：乙酸乙酯：石油醚＝1：5)，得250毫克化合物71，收率57％。本发明的其他通式I化合物可参照上述方法合成。
本发明的其他通式I化合物可参照上述方法合成。
生物活性测定实施例
实施例3杀菌活性的测定
用本发明化合物对植物的多种病害进行了试验。试验的方法如下：
采用活体盆栽测定方法，即将待测化合物样品用少量溶剂(溶剂的种类如丙酮、甲醇、DMF等，依据其对样品的溶解能力而选择，溶剂量与喷液量的体积比等于或小于0.05。)溶解，用含有0.1％吐温80的水稀释，配制成所需浓度待测液。用本发明化合物按照设计浓度进行叶面喷雾处理。另设喷清水的空白对照，3次重复，处理后第二天进行病害接种。接种后，将植物放在人工气候室中保湿培养(温度：昼25℃、夜20℃，相对湿度：95-99％)。试验材料培养24h后，移置温室培养，将不需要保湿培养的植物直接在温室内接种并培养。待对照充分发病后(通常为一周时间)进行化合物防病效果评估。结果调查参照美国植病学会编写的《A Manual of Assessment Keys for Plant Diseases》，用100～0来表示，以“100”级代表无病和“0”级代表最严重的发病程度。
部分测试结果如下：
对黄瓜炭疽病的防效：
按照以上测试方法，部分供试的化合物中，下列化合物在浓度为400ppm时防治效果较好，防效≥80％：化合物4。
对黄瓜霜霉病的防效：
按照以上测试方法，部分供试的化合物中，下列化合物在浓度为400ppm时防治效果较好，防效≥80％：化合物2、4、11、13、36、70、71、102、110和111。
按照以上测试方法，选取本发明化合物2、4、11、13、71和111与已知化合物KC1、KC2、KC3、KC4、KC5和KC6进行防治黄瓜霜霉病活性的平行测定(对照化合物均为自制，结构经核磁共振氢谱确认与现有公开文献描述的一致)，试验结果见表2。
表2：部分本发明化合物与已知化合物对黄瓜霜霉病防效的比较
Figure PCTCN2016080952-appb-000022
Figure PCTCN2016080952-appb-000023
对玉米锈病的防效：
按照以上测试方法，部分供试的化合物中，下列化合物在浓度为400ppm时对玉米锈病的防治效果较好，防效≥80％：化合物2、4、11、13、71、72、102、109、110、111和112。
按照以上测试方法，选取化合物13与已知化合物KC1进行了防治玉米锈病活性的平行测定。试验结果见表3。
表3：部分本发明化合物与已知化合物对玉米锈病防效的比较
Figure PCTCN2016080952-appb-000024
按照以上测试方法，选取化合物11与已知化合物KC2进行了防治玉米锈病活性的平行测定。试验结果见表4。
表4：部分本发明化合物与已知化合物对玉米锈病防效的比较
Figure PCTCN2016080952-appb-000025
按照以上测试方法，选取化合物71与已知化合物KC5和KC6进行了防治玉米锈病活性的平行测定。试验结果见表5。
表5：部分本发明化合物与已知化合物对玉米锈病防效的比较
Figure PCTCN2016080952-appb-000026

Claims (10)

  1. 一种酰胺类化合物，其特征在于：酰胺类化合物如通式I所示：
    Figure PCTCN2016080952-appb-100001
    式中：
    R1、R2、R3、R4、R5、R6分别独立地选自氢、卤素、氰基、C1～C12的烷基、C1～C12的烷氧基、C1～C12的卤代烷基、C3～C6的环烷基、C3～C6的卤代环烷基、C2～C6的烯基、C2～C6的炔基、羟基-C1～C6的烷基、C1～C6的烷氧基-C1～C6的烷基、C3～C6的环烷基-C1～C6的烷基氧基-C1～C6的烷基、C1～C6的卤代烷氧基-C1～C6的烷基、C3～C8烯基氧基-C1～C6的烷基、C3～C8炔基氧基-C1～C6的烷基、芳基-C1～C6的烷氧基-C1～C6的烷基、C1～C6的烷氧基羰基、C1～C6的卤代烷氧羰基、C3～C6的环烷氧基羰基、C3～C6的卤代环烷氧羰基、C3～C6的环烷基-C1～C6的烷氧基羰基、芳基氧羰基、C1～C6的烷基胺基羰基、C3～C6的环烷胺基羰基、C3～C6的环烷基-C1～C6的烷胺基羰基、芳基胺基羰基、芳基-C1～C6的烷胺基羰基，以及上述芳基-C1～C6的烷氧基-C1～C6的烷基、芳基氧羰基、芳基胺基羰基、芳基-C1～C6的烷胺基羰基中芳基被至多6个相同或不同的R7取代后的基团；
    其中芳基选自苯环、具有1～3个杂原子的5或6元杂环或苯并具有1～3个杂原子的5或6元杂环；
    R7选自卤素、硝基、氰基、C1～C6的烷基或C1～C6的卤代烷基；
    Q选自Q1或Q2
    Figure PCTCN2016080952-appb-100002
    R8选自C1～C3的烷基、C1～C3的卤代烷基或C3～C6的环烷基；
    R9选自氢、卤素或甲基；
    其中，当R8选自二氟甲基时，R9不为氢；
    R10和R11分别独立地选自C1～C6的烷基、C1～C6的卤代烷基或C3～C6的环烷基。
  2. 按照权利要求1所述的化合物，其特征在于，通式I中：
    R1、R2、R3、R4、R5、R6分别独立地选自氢、卤素、氰基、C1～C12的烷基、C1～C6的烷氧基、C1～C6的卤代烷基、C3～C6的环烷基、C3～C6的卤代环烷基、C2～C6的烯基、C2～C6的炔基、羟基-C1～C3的烷基、C1～C3的烷氧基-C1～C3的烷基、C3～C6的环烷基-C1～C3的烷基氧基-C1～C3的烷基、C1～C3的卤代烷氧基-C1～C3的烷基、C3～C6烯基氧基-C1～C3的烷基、C3～C6炔基氧基-C1～C6的烷基、芳基-C1～C3的烷氧基-C1～C3的烷基、C1～C3的烷氧基羰基、C1～C3的卤代烷氧羰基、C3～C6的环烷氧基羰基、C3～C6的卤代环烷氧羰基、C3～C6的环烷基-C1～C3的烷氧基羰基、芳基氧羰基、C1～C3的烷基胺基羰基、C3～C6的环烷胺基羰基、C3～C6的环烷基-C1～C3的烷胺基羰基、芳基胺基羰基、芳基-C1～C3的烷胺基羰基，以及上述芳基-C1～C6的烷氧基-C1～C6的烷基、芳基氧羰基、芳基胺基羰基、芳基-C1～C6的烷胺基羰基中芳基被至多6个相同或不同的R7取代后的基团；
    其中为芳基选自苯环、具有1～3个杂原子的5或6元杂环或苯并具有1～3个杂原子的5或6元杂环；
    R7选自卤素、硝基、氰基、C1～C3的烷基或C1～C3的卤代烷基；
    在所述Q2中，R10和R11分别独立地选自C1～C3的烷基、C1～C3的卤代烷基或C3～C6的环烷基。
  3. 按照权利要求2所述的化合物，其特征在于，通式I中：
    R1、R2、R3、R4、R5、R6分别独立地选自氢、氟、氯、溴、碘、氰基、C1～C12的烷基、C1～C3的烷氧基、C1～C6的卤代烷基、C3～C6的环烷基、C3～C6的卤代环烷基、C2～C6的烯基、C2～C6的炔基、羟基-C1～C3的烷基、C1～C3的烷氧基-C1～C3的烷基、C3～C6的环烷基-C1～C3的烷基氧基-C1～C3的烷基、C1～C3的卤代烷氧基-C1～C3的烷基、C3～C6烯基氧基-C1～C3的烷基、C3～C6炔基氧基-C1～C6的烷基、芳基-C1～C3的烷氧基-C1～C3的烷基、C1～C3的烷氧基羰基、C1～C3的卤代烷氧羰基、C3～C6的环烷氧基羰基、C3～C6的卤代环烷氧羰基、C3～C6的环烷基-C1～C3的烷氧基羰基、芳基氧羰基、C1～C3的烷基胺基羰基、C3～C6的环烷胺基羰基、C3～C6的环烷基-C1～C3的烷胺基羰基、芳基胺基羰基、芳基-C1～C3的烷胺基羰基，以及上述芳基-C1～C6的烷氧基-C1～C6的烷基、芳基氧羰基、芳基胺基羰基、芳基-C1～C6的烷胺基羰基中的芳基被至多6个相同或不同的R7取代后的基团；
    其中为芳基选自苯环、呋喃、噻吩、吡咯、吡唑、噁唑、异噁唑、噻唑基、吡啶、吡嗪、嘧啶、哒嗪、苯并噁唑、苯并噻唑、喹喔啉或喹唑啉基；
    R7选自氟、氯、溴、碘、硝基、氰基、C1～C3的烷基或C1～C3的卤代烷基。
  4. 按照权利要求3所述的化合物，其特征在于，通式I中：
    R1选自氟、C1～C3的烷基或C1～C3的卤代烷基；
    R2、R3、R4、R5分别独立地选自氢、氟、C1～C3的烷基或C1～C3的卤代烷基；
    R6选自C1～C12的烷基；
    在所述Q1中，R8选自甲基、乙基、正丙基、异丙基、三氟甲基、二氟甲基、五氟乙基、七氟异丙基或环丙基；
    R9选自氢、氟、氯、溴、碘或甲基；
    在所述Q2中，R10和R11分别独立地选自甲基、乙基、丙基、异丙基、环丙基、二氟甲基、三氟甲基、五氟乙基或七氟异丙基。
  5. 按照权利要求4所述的化合物，其特征在于，通式I中：
    R1选自C1～C3的烷基；
    R2、R3、R4、R5分别独立地选自氢；
    在所述Q1中，R8选自甲基或二氟甲基；
    R9选自氟或氯；
    在所述Q2中，R10和R11分别独立地选自甲基、二氟甲基、三氟甲基或环丙基。
  6. 按照权利要求5所述的化合物，其特征在于，通式I中：
    R1选自C1～C3的烷基；
    R2、R3、R4、R5分别独立地选自氢；
    R6选自C1～C6的烷基。
  7. 一种按照权利要求1所述的酰胺类化合物的制备方法，反应式如下：
    Figure PCTCN2016080952-appb-100003
    式中：
    L离去基团、X代表卤素；R1、R2、R3、R4、R5和R6如上所定义。
  8. 一种按照权利要求1所述的酰胺类化合物用于制备作为农业、林业领域中杀菌剂药物的用途。
  9. 一种杀菌组合物，其特征在于：含有如权利要求1所述的酰胺类化合物为活性组分和农业、林业上可接受的载体，且所述组合物中作为活性组分的酰胺类化合物的重量含量为1-99％。
  10. 一种控制病菌的方法，其特征在于：将权利要求9所述的组合物以每公顷10克到1000克的有效剂量施于需要控制的病菌或其生长的介质上。
PCT/CN2016/080952 2015-05-06 2016-05-04 一种酰胺类化合物及其制备方法和用途 WO2016177318A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US15/551,401 US10315998B2 (en) 2015-05-06 2016-05-04 Amide compound and the preparation method and use thereof
EP16789312.2A EP3293179A4 (en) 2015-05-06 2016-05-04 Amide compound and the preparation method and use thereof
CN201680004319.9A CN107108515B (zh) 2015-05-06 2016-05-04 一种酰胺类化合物及其制备方法和用途
BR112017014498-0A BR112017014498B1 (pt) 2015-05-06 2016-05-04 Composto de amida e o método de preparação e uso do mesmo

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201510226412.1A CN106187893B (zh) 2015-05-06 2015-05-06 一种吡唑酰胺类化合物及其用途
CN201510226786.3A CN106187939B (zh) 2015-05-06 2015-05-06 一种噻唑酰胺类化合物及其用途
CN201510226786.3 2015-05-06
CN201510226412.1 2015-05-06

Publications (1)

Publication Number Publication Date
WO2016177318A1 true WO2016177318A1 (zh) 2016-11-10

Family

ID=57218079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/080952 WO2016177318A1 (zh) 2015-05-06 2016-05-04 一种酰胺类化合物及其制备方法和用途

Country Status (5)

Country Link
US (1) US10315998B2 (zh)
EP (1) EP3293179A4 (zh)
CN (1) CN107108515B (zh)
BR (1) BR112017014498B1 (zh)
WO (1) WO2016177318A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104649973B (zh) * 2013-11-25 2017-02-15 沈阳中化农药化工研发有限公司 一种吡唑酰胺类化合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5657776A (en) * 1979-10-17 1981-05-20 Kumiai Chem Ind Co Ltd Thiazole derivative and fungicide comprising it
CN104649973A (zh) * 2013-11-25 2015-05-27 中国中化股份有限公司 一种吡唑酰胺类化合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62249975A (ja) * 1986-04-22 1987-10-30 Sumitomo Chem Co Ltd アニリド誘導体およびそれを有効成分とする殺菌剤
US5045554A (en) 1988-11-29 1991-09-03 Monsanto Company Substituted thiazoles and their use as fungicides
EP2253623B1 (en) 2005-09-16 2013-10-23 Syngenta Participations AG. New crystal form of a pyrazole fungicide
WO2012065947A1 (en) * 2010-11-15 2012-05-24 Bayer Cropscience Ag 5-halogenopyrazolecarboxamides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5657776A (en) * 1979-10-17 1981-05-20 Kumiai Chem Ind Co Ltd Thiazole derivative and fungicide comprising it
CN104649973A (zh) * 2013-11-25 2015-05-27 中国中化股份有限公司 一种吡唑酰胺类化合物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3293179A4 *

Also Published As

Publication number Publication date
US10315998B2 (en) 2019-06-11
CN107108515B (zh) 2019-08-02
CN107108515A (zh) 2017-08-29
EP3293179A1 (en) 2018-03-14
EP3293179A4 (en) 2018-09-19
BR112017014498A2 (pt) 2018-01-09
BR112017014498B1 (pt) 2022-05-31
US20180029991A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
WO2015074614A1 (zh) 一种吡唑酰胺类化合物及其用途
CZ20032018A3 (cs) Karboxamidy, způsob jejich přípravy a jejich použití k ochraně rostlin
WO1996019442A1 (fr) Derive de benzamidoxime, procede de production, et bactericide agrohorticole
BRPI0617171A2 (pt) compostos tiazóis, processo para produção e uso dos mesmos, agente para o combate de microorganismos indesejáveis, processo para o dito combate, processo de produção de agentes para o combate e produtos intermediários
CN106187893B (zh) 一种吡唑酰胺类化合物及其用途
CN108069984B (zh) 含嘧啶并环的取代五元杂环类化合物及其制备方法和用途
CN108059614B (zh) 吡唑酰胺类化合物及其应用
WO2016177318A1 (zh) 一种酰胺类化合物及其制备方法和用途
Yang et al. Synthesis and antiviral bioactivities of novel chiral bis-thiourea-type derivatives containing α-aminophosphonate moiety
CN105646395B (zh) 一种噻唑酰胺类化合物及其应用
CN112624989A (zh) 一种酰胺类化合物及其应用
CN114763331B (zh) 一种三氟乙基硫醚（亚砜）取代苯类化合物及其用途
CN108059613B (zh) 一种吡唑酰胺类化合物及应用
CN106187939B (zh) 一种噻唑酰胺类化合物及其用途
CN113387926B (zh) 一种杂环羧酸酯类化合物及其作为除草剂的用途
CN111285807B (zh) 一种吡唑酰胺类化合物及其用途
CN105712973B (zh) 一种吡唑酰胺类化合物及其应用
CN109574956B (zh) 一种噻二唑酰胺类化合物及其应用
CN106431977B (zh) 一种不饱和肟醚类化合物及其用途
CN111285815A (zh) 一种吡嗪酰胺类化合物及用途
CN110963963A (zh) 一种吡啶酰胺类化合物及其杀菌用途
CN108610283B (zh) 一种仲胺类化合物及其制备和应用
CN103833670B (zh) 2-氯噻唑基丙烯腈类化合物及其应用
WO2010069495A1 (de) Atpenine
CN109867666B (zh) 一种含异噻唑环的芳乙酰胺类化合物及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16789312

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2016789312

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017014498

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 112017014498

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170704